Abstract
This response refers to:Xu, Z.; Liu, Y.; Zhou, S.; Fu, Y.; Li, C. Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques. Int. J. Mol. Sci. 2016, 17, 1042.Merlot, A.M.; Sahni, S.; Lane, D.J.R.; Richardson, V.; Huang, M.L.H.; Kalinowski, D.S.; Richardson, D.R. Letter to the Editor: Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques and. Int. J. Mol. Sci. 2016, 17, 1916.
Highlights
Response to the Letter to the Editor by D
Dear Editors, Thank you for forwarding the concerns from Dr Richardson [1] regarding our paper “Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques” [2], which was recently published in the International Journal of Molecular Sciences
The paper examines the binding of the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3thiosemicarbazone (Dp44mT), to human serum albumin (HSA) and DNA and states that “no studies have examined the effects of the interaction between Dp44mT and biological molecules, such as proteins and nucleic acids”
Summary
Response to the Letter to the Editor by D. Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
